Citius Oncology (CTOR) Financial Ratios

For fiscal 2025 (fiscal year ended Sep 30, 2025), Citius Oncology had return on equity of -54.4% (up from -59.0%), debt-to-equity of 0.09 (up from 0.08), a current ratio of 0.56 (up from 0.34) and return on assets of -15.9% (up from -19.5%). A current ratio of 0.56 means current liabilities exceed current assets.

Citius Oncology Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Dec 2021
Valuation Ratios
Forward P/E	89.00	-	-	-	-
P/B Ratio	3.78	2.15	3.77	-	-
Price/Tangible Book	3.78	2.15	3.77	-	-
Price/OCF	-	784.41	-	-	-
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-54.42%	-59.01%	-41.09%	-	-
Return on Assets (ROA)	-15.87%	-19.47%	-16.76%	-	-
Return on Capital Employed (ROCE)	-45.70%	-39.80%	-45.40%	-26.40%	-
Leverage & Solvency Ratios
Debt/Equity	0.09	0.08	-	-	-
Liquidity Ratios
Current Ratio	0.56	0.34	0.37	0.46	-
Quick Ratio	0.08	0.00	-	-	-
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield	-14.61%	-21.34%	-13.19%	-	-
Buyback Yield	-7.66%	-0.82%	-100.00%	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Citius Oncology Financial Ratios

What is Citius Oncology's return on equity?

Citius Oncology's return on equity (ROE) was -54.4% for fiscal 2025 (period ended Sep 30, 2025). It was -59.0% a year earlier.

What is Citius Oncology's debt-to-equity ratio?

Citius Oncology's debt-to-equity ratio was 0.09 for fiscal 2025 (period ended Sep 30, 2025). It was 0.08 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition